**RELATIONSHIP BETWEEN SARCOPENIA AND ORTHOSTATIC HYPOTENSION IN OLDER ADULTS**

**Pinar Soysal1, Suleyman Emre Kocyigit2, Ozge Dokuzlar2, Esra Ates Bulut2,**

**Lee Smith3, Ahmet Turan ISIK2**

1Department of Geriatric Medicine, Bezmialem Vakif University, Faculty of Medicine, Istanbul

2 Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.

3The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, United Kingdom

**Corresponding Author**: Pinar SOYSAL, Associate Prof

Department of Geriatric Medicine, Bezmialem Vakif University, Faculty of Medicine, Istanbul,

Turkey

Full Postal Address: Adnan Menderes Bulvarı (Vatan Street) Postal code: 34093 Fatih , İstanbul,

Turkey

**E-mail**: dr.pinarsoysal@hotmail.com; Phone: +90 212 4531700 Fax: +90 212 4531869

**Financial Disclosure Statement**: No funding sources.

**Author Contributions:** Study design: Soysal, Isik; Methods: All authors; Data collection: Kocyigit, Dokuzlar, Ates Bulut; Analysis and interpretation of data: Kocyigit, Smith, Soysal and Isik; Preparation of the manuscript: Soysal and Isik

**ABSTRACT (250/250)**

**Background:** The relationship between sarcopenia and orthostatic hypotension (OH) is unclear.

**Objectives:** Theaim of the present study was to investigate associations between sarcopenia/sarcopenia severity and OH.

**Design:** 511 patients attending a geriatric outpatient clinic were included. OH was defined as a decrease in systolic and/or diastolic blood pressure of ≥20 mmHg and/or ≥10 mmHg, respectively, when one transitions from the supine to an upright position. OH was measured by the Head-up Tilt Table test at 1, 3, and 5 minutes (OH1, OH3, and OH5, respectively). Sarcopenia and severity were defined according to the revised European consensus on definition and diagnosis.

**Results:**The mean age of the sample was 75.40±7.35 years and 69.9% were female.The prevalence of probable sarcopenia, sarcopenia and severe sarcopenia was 42.2%, 6.06% and 11.1%, respectively.  After adjustment for all covariates, systolic OH1, OH1 and systolic OH5 were statistically significant between severe sarcopenia and the robust group (Odd Ratio (OR):3.26 Confidence Interval [CI] 0.98-10.84; p=0.05 for systolic OH1, OR:4.31 CI 1.31-14.15; p=0.016 for OH1, OR:4.09 CI 1.01-16.55; p=0.048 for systolic OH5). Only systolic OH1 was statistically different between sarcopenia and severe sarcopenia groups (OR:2.64 CI; 1.87-8.73; p=0.012). OH1 and OH5 were statistically significant between severe sarcopenia and probable sarcopenia groups (p<0.05), there was no relationship between the robust group and probable sarcopenia (p>0.05).

**Conclusions:**There is a close relationship between sarcopenia and severe sarcopenia and OH in older adults. Therefore, when a healthcare practitioner is evaluating an older patient with sarcopenia, OH should also be evaluated and vice versa.

**Keyword:** sarcopenia, orthostatic hypotension, geriatric assessment

**Key points:**

* There is an association between sarcopenia and orthostatic hypotension.
* The greater the severity of sarcopenia, the stronger the association is with orthostatic hypotension.
* Decreased muscle mass, rather than muscle strength, is associated with orthostatic hypotension.

**INTRODUCTION**

With advancing age, there is a significant decrease in compensatory organ functions that provide homeostatic balance in the body [1] . Orthostatic (postural) hypotension (OH) is one health consequence resulting from a deterioration in homeostasis [1]. While the prevalence of OH is less than 5% before the age of 65 years, it is stated that this rate exceeds 30% for those aged 70 years and over [1]. OH causes cardiovascular events, recurrent falls, depression, stroke, cognitive impairment, and mortality in geriatric patients [2–5]. Recently, it has been argued that OH may be a new geriatric syndrome rather than a cardiovascular condition [4]. Therefore, early detection of risk factors for developing OH is important.

OH is defined as a decrease in systolic blood pressure of 20 mmHg and above and / or a decrease in diastolic blood pressure of 10 mmHg in the first 3 minutes of transition from the supine position to the upright position [6]. While the patient is standing up a normal rise in systolic blood pressure of 5-10 mmHg and a rise in diastolic blood pressure of 5-10 mmHg are considered physiological, termed orthostatic stability in healthy individuals, and is a consequence of neurohumoral and venous pump activation (muscle contractions) over approximately 60 seconds [1,7]. However, decreased arterial baroreceptor sensitivity and renin angiotensin-aldosterone levels through aging, cardiac hypertrophy and the failure of the autonomic nervous system increase the risk of developing OH [7]. One mechanism contributing to the development of OH is a decrease in venous circulation of blood pooled in the lower half of the body owing to gravity [8] . The mechanism is impaired as a result of the inadequate response of the skeletal muscle pumps to changes in the circulatory system, and the decrease in skeletal muscle contraction of the legs in older adults, leading to the hypothesis that sarcopenia, an important geriatric syndrome, is likely to cause OH.

This hypothesis has also been supported by some studies indirectly. For example, research has shown that sarcopenia, sarcopenic obesity and low muscle mass may increase the risk of developing OH by increasing insulin resistance and inflammation and causing arterial stiffness [9]. For example, Zhang et al. reported that high brachial-ankle pulse wave velocity, indicative of arterial stiffness, was associated with sarcopenia [9]. In another study, reduced muscle mass was an independent risk factor for increased arterial stiffness [10]. Indeed, arterial stiffness leads to a decrease in the sensitivity of baroreceptors that control arterial blood pressure, causing OH [11].Moreover, one of the most important causes of OH is autonomic dysfunction, and recent studies have shown that there is impairment in muscle sympathetic nerve activity due to reduced muscle mass in sarcopenia, leading to sympatho-vagal imbalance, and OH [12,13].

In recent years it has been reported that OH may be caused by frailty and malnutrition, which are closely associated with sarcopenia [14,15]. However, to the best of our knowledge, no study has been conducted to date to examine the relationship between sarcopenia and OH. For this reason, the aim of the present study was to investigate associations between sarcopenia and its severity with OH.

 **METHODS**

**Inclusion criteria**

A total of 849 older patients attended (referred by a clinician or self-referred), for any health issue, one outpatient clinic between September 2016 and October 2018. This clinic is located in the department of geriatric medicine at the university teaching hospital, Dokuz Eylul University in Izmir, Turkey.

511 patients without any exclusion criteria, were included in this cross-sectional study (Figure 1). The investigation conformed to the Declaration of Helsinki and was approved by the local ethics committee. Informed consent was provided by each participant or a legal surrogate.

 **Exclusion criteria**

* Patients with severe osteoarthritis or neuromuscular disease, which causes an obstacle to walking, and immobile patients.
* Patients with any contraindications for Head up Tilt Table test (HUT) [14]
* Patients with alcohol and substance abuse.
* Patients with a pacemaker (because of contraindication to electrical bioimpedance).
* Patients under 65 years of age and those who refused to participate.

**Patient characteristics**

Patients' age, gender, level of education, concurrent systemic and chronic diseases, and number of medications used were determined by patients' self or caregiver’ report. During admission they were asked whether they had fallen in the previous year. Dementia, and depression were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria.

**Comprehensive geriatric assessment**

Patients had a specialist evaluation by a geriatrician, during which the following assessment scales were routinely completed: Mini Mental State Examination (MMSE), Yesevage Geriatric Depression Scale (GDS) for neurocognitive evaluation, Basic and Instrumental Activities of Daily Living (BADL, IADL) for functionality evaluation, Timed Up and Go test and Tinetti Performance-Oriented Assessment of Mobility (POMA) for mobility evaluation, Mini Nutritional Assessment (MNA) for nutritional evaluation [16] .

**Laboratory ﬁndings**

Laboratory tests, including renal and liver functions, fasting blood glucose, hemogram, TSH, vitamin D, vitamin B12 and folic acid levels were performed to evaluate the biochemical, metabolic and nutritional status of the patients, all of which were obtained with the auto-analyzer diagnostic modular system (Roche E170 and P-800). Serum 25-hydroxy D vitamin [25(OH) D] was measured by radioimmunoassay.

**Diagnosis of sarcopenia**

For the evaluation of walking speed, muscle strength and muscle mass, 4-meter walking test, handgrip test, and bioimpedance were performed for each patient, respectively. Handgrip test was measured by JAMAR branded hand dynamometer, and bioimpedance was established using TANITA scales (MC-780U Multi Frequency Segmental Body Composition). Slow walking speed was categorized as <0.8 m/s, and low handgrip strength in women as <16 kg, in males as <27 kg [17] . The muscle mass index score of <8.87 kg/m2 was regarded as low muscle mass for males and <6.42 kg/m2 for females [17] . Probable sarcopenia, sarcopenia and severe sarcopenia were identified according to revised EWGSOP [17,18]. The robust group included those patients without probable sarcopenia, sarcopenia and severe sarcopenia.

**Diagnosis of OH**

OH was evaluated using HUT [14]. HUT was conducted using the Tilt Table (Gemesan1 Tilt TableG-71, Turkey). Monitoring over the course of HUT was performed using the Biolight1 BIOM69 (Australia). The patients were monitored for blood pressure over the course of HUT. The data were obtained from measurements recorded in the 1st, 3rd, and 5th minutes. Continuous beat-to-beat blood pressure measurements were not obtained. OH was defined as a decrease in systolic and/or diastolic blood pressure of ≥20 mmHg and/or ≥10 mmHg, respectively, when one transitions from a supine to an upright position. For example, the diagnosis of OH in the 1st minute was made by the presence of systolic OH in the 1st minute and/or diastolic OH in the 1st minute.

**Statistical analyses**

Data were analyzed using SPSS for Windows 15. Descriptive statistics are shown as mean ± standard deviation for variables with normal distribution, median (minimum to maximum) for non-normal distributions, and the number of cases and percentage (%) for nominal variables. When the group number was two, the significance of differences between the groups in terms of averages was investigated by t-test and in terms of median values was investigated by Mann Whitney test. When the number of groups was more than two or the variables were not normally distributed, the signiﬁcance of medians was determined by the Kruskal Wallis test. Nominal variables were assessed by Pearson Chi-Square or Fisher Exact test. Binary logistic regression analysis was performed within two groups adjusted for confounding variables. Odds ratios were calculated. p<0.05 was considered statistically signiﬁcant. In a review carried out by Frith et al. (2017), it was identified that the frequency of OH in community-dwelling people aged ≥65 years was 30%. Therefore, at least 269 patients were required to be recruited into the present study, to achieve a level of 5% acceptable error and 95% confidence [19].

**RESULTS**

 The prevalence of probable sarcopenia, sarcopenia and severe sarcopenia were 42.2%, 6.06% and 11.1%, respectively. Of 511 older patients, 69.9% were female and the mean age was 75.40±7.35 years. Age, gender, education year, BMI, falls history, presence of dementia, level of hemoglobin, albumin, MMSE, YGDS, Tinetti-gait and balance scores, Timed up and go test score, ADLs and MNA score were statistically different within groups according to revised EWGSOP criteria (p<0.05) (Table 1). Additionally, number of drugs used, eGFR and level of 25(OH) D were statistically significant within groups (p<0.05, Table 1). The rates of systolic OH1, OH1 and OH5 were different within groups (p<0.05, Table 1).

In binary logistic regression analysis, adjusted for age, BMI, gender, education year, falls history, presence of dementia, MMSE, YGDS, Tinetti-gait, balance and total test, Timed up and go test score, ADLs (Barthel and Lawton), and MNA score, the systolic OH1, OH1 and systolic OH5 were statistically significant between severe sarcopenia and the robust group (Odd Ratio (OR):3.26 Confidence Interval [CI] 0.98-10.84; p=0.05 for systolic OH1, OR:4.31 CI 1.31-14.15; p=0.016 for OH1, OR: 4.09 CI 1.01-16.55; p=0.048 for systolic OH5). Only systolic OH1 was statistically different between sarcopenia and severe sarcopenia groups (OR:2.64 CI; 1.87-8.73; p=0.012). OH1 and systolic OH5 and OH5 were statistically significant between severe sarcopenia and probable sarcopenia groups (OR: 3.50 CI 1.34-9.11; p=0.010 for OH1, OR: 3.24 CI 1.13-9.23; p=0.009 for systolic OH5, OR: 3.50 CI 1.31-9.35; p=0.004 for OH5) (Table 2). All aforementioned odds ratios showed a positive correlation. There was no relationship between robust and probable sarcopenia after logistic regression analysis as well as between the other binary groups without logistic regression analysis (p>0.05).

When the relationships between OH, and low muscle power, low walking speed, low muscle mass were assessed (adjusted for: age, presence of dementia, fall history, Timed up and go score and ADLs scores), OH3, systolic OH5 and OH5 were found to be associated with lower muscle mass (p<0.05); systolic OH1, OH1, systolic OH3, diastolic OH5 and OH5 with lower walking speed (p<0.05); yet, OH was not associated with lower muscle power (p>0.05, Table 3).

**DISCUSSION**

Findings from the present study suggest that there is a close relationship between sarcopenia and OH, especially in the 1st and 5th minutes, which increases as the severity of sarcopenia does. Moreover, decreased muscle mass and lower walking speed were found to be closely related to OH rather than a decrease in muscle strength.

Sarcopenia, one of the geriatric syndromes, has attracted attention for the last 3 decades [17] . Although revised criteria for sarcopenia were published in 2019, the number of studies using these criteria is small. In the present study, in which EWGSOP2 criteria were applied, 40% of the patients had no sarcopenia, whereas 11% had severe sarcopenia. Similar results were obtained in a study using EWGSOP1 criteria and including geriatric outpatients [20]. The high prevalence of sarcopenia is remarkable in older adults because sarcopenia is known not only as a simple muscle disease but also to affect many organ systems, particularly the respiratory and cardiovascular system.

Not surprisingly, this study found that the severity of sarcopenia/sarcopenia was associated with the development of OH, which can be explained by several mechanisms: First, sarcopenia can lead to a reduction in effective venous return, since venous pumps in the leg muscles pump blood from the lower extremity to the heart, which is important in maintaining cardiac filling pressure [21,22]. To date there is no other study investigating the relationship between sarcopenia and OH. However, some studies indirectly support the present findings. For example, Suzuki et al., using a sample of young adults reported that there was a decrease in venous return and cardiac output following 20-day bed rest, due to the decrease in muscle mass and muscle strength, and that patients had deterioration in orthostatic tolerance capacity [23]. In another study, it was found that calf circumference, which has a negative close correlation with appendicular skeletal muscle mass, could be used for OH screening in older adults [23]. Moreover, isometric contraction of the muscles under the waist, which plays a role in maintaining blood pressure when one stands-up by increasing venous return, is recommended for the prevention of OH [24,25]. This maneuver, which is well known for its effect on OH management, may actually indicate the importance of muscle mass and sarcopenia in the development of OH. In addition, in a study including 37 patients, sarcopenia was diagnosed by Skeletal Muscle Index (SMI); lower systolic blood pressure was more common in those with, rather than those without, sarcopenia. However, there was no correlation with OH, which may be owing to the low sample size of the study [26]. The results of these studies are consistent with the present findings, which clearly reveal the relationship between sarcopenia and OH, suggesting that it is a consequence in a reduction of skeletal muscle mass rather than muscle strength. According to findings from this study, skeletal muscle pump activity that provides venous return is an important factor in maintaining systolic blood pressure regulation and the main factor determining this is muscle mass. Thus, sarcopenia seems to affect not only the muscular system but also cardiovascular functions. As a result, sarcopenia may impair the compensatory response to orthostatic changes in older adults, leading to early (1 minute) and delayed (5 minutes) OH development after stand-up [27]. Although the cause is not known exactly, OH in the first minute is shown to be more important for geriatric practice in older adults [26]. For example, in a study using HUT similar to that in this study, a relationship was found between frailty and OH only in the first minute, but sarcopenia was not evaluated in this study [14]. In another study, Juraschek et al. suggested that OH should be assessed within 1 minute of standing, as it was found that OH1 was most strongly related to dizziness and individual adverse outcomes including fall, fracture, and syncope [28]. Therefore, sarcopenia may also have contributed to the development of OH and the outcomes in the first minute in those studies. According to the present findings, decreased muscle mass associated with OH in the fifth minute rather than in the first and the third minute is also noteworthy. It is possibly an indication that venous blood return cannot be sustained by muscle mass throughout standing. Moreover, in older adults, OH may play a role in the reduction of muscle mass and sarcopenia by causing falls, balance and gait problems, and possibly making patients less mobile [3,5]. Indeed, in this study, falling history, a decrease in gait and balance functions evaluated by Tinetti test, and a decrease in functionality evaluated by BADL and IADL were frequent, specifically in the severe sarcopenia group. However, further longitudinal studies are needed to display the relationships between sarcopenia and OH.

The present study has several strengths. For the diagnosis of OH, the gold standard methods, HUT test, and for the diagnosis of sarcopenia, EWGSOP2 criteria were used. Other strengths include the provision of adequate sample size and the evaluation of other risk factors, such as comorbid diseases and medication. However, findings should be interpreted in light of the studies limitations. First, this study is cross-sectional in nature. Therefore, it is not known whether OH leads to sarcopenia or whether sarcopenia leads to OH. It is possible that the relationship is bidirectional. Thus, further longitudinal studies are now required for the determination of causality. Second, because there was no data on inflammation and oxidative stress makers, heart rate variability or brachial-ankle pulse wave velocity, the mechanism underlying the association between sarcopenia and OH cannot be clarified. The blood pressure data beyond five minutes of HUT were not collected and it is therefore unclear how the results would be affected by prolonged standing. In addition, the exclusion of older patients due to the contraindications for HUT is a limitation. Lastly, 30 minutes may not be an adequate length of time to avoid smoking, consuming caffeine and exercising prior to HUT.

OH and sarcopenia are two major geriatric syndromes that are closely related. Moreover, the greater the severity of sarcopenia, the stronger the relationship is with OH. Therefore, when evaluating older adults with sarcopenia in geriatric practice, OH should also be evaluated and vice versa. Thus, more effective management of the two will be possible and common complications due to both may be reduced.

**Funding and conflict of interest:** None declared

**REFERENCES**

1. Ricci F, De Caterina R, Fedorowski A. Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. J Am Coll Cardiol. 2015 Aug;66(7):848–60.

2. Rawlings AM, Juraschek SP, Heiss G, Hughes T, Meyer ML, Selvin E, et al. Association of orthostatic hypotension with incident dementia, stroke, and cognitive decline. Neurology. 2018 Aug;91(8):e759–68.

3. Mol A, Bui Hoang PTS, Sharmin S, Reijnierse EM, van Wezel RJA, Meskers CGM, et al. Orthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis. J Am Med Dir Assoc. 2019 May;20(5):589-597.e5.

4. Chen L, Xu Y, Chen X-J, Lee W-J, Chen L-K. Association between Orthostatic Hypotension and Frailty in Hospitalized Older Patients: a Geriatric Syndrome More Than a Cardiovascular Condition. J Nutr Health Aging. 2019;23(4):318–22.

5. Soysal P, Veronese N, Smith L, Torbahn G, Jackson SE, Yang L, et al. Orthostatic hypotension and health outcomes: an umbrella review of observational studies. Eur Geriatr Med. 2019;

6. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996 May;46(5):1470.

7. Robertson D. The pathophysiology and diagnosis of orthostatic hypotension. Clin Auton Res. 2008 Mar;18 Suppl 1:2–7.

8. Magkas N, Tsioufis C, Thomopoulos C, Dilaveris P, Georgiopoulos G, Sanidas E, et al. Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations. J Clin Hypertens (Greenwich). 2019 May;21(5):546–54.

9. Zhang L, Guo Q, Feng B-L, Wang C-Y, Han P-P, Hu J, et al. A Cross-Sectional Study of the Association between Arterial Stiffness and Sarcopenia in Chinese Community-Dwelling Elderly Using the Asian Working Group for Sarcopenia Criteria. J Nutr Health Aging. 2019;23(2):195–201.

10. Tanaka K-I, Kanazawa I, Sugimoto T. Reduced muscle mass and accumulation of visceral fat are independently associated with increased arterial stiffness in postmenopausal women with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016 Dec;122:141–7.

11. Meng Q, Wang S, Wang Y, Wan S, Liu K, Zhou X, et al. Arterial stiffness is a potential mechanism and promising indicator of orthostatic hypotension in the general population. Vasa. 2014 Nov;43(6):423–32.

12. Fonseca GWP da, Santos MR Dos, Souza FR de, Costa MJA da, Haehling S von, Takayama L, et al. Sympatho-Vagal Imbalance is Associated with Sarcopenia in Male Patients with Heart Failure. Arq Bras Cardiol. 2019 Jun;112(6):739–46.

13. Freitas VP de, Passos R da S, Oliveira AA, Ribeiro IJS, Freire IV, Schettino L, et al. Sarcopenia is associated to an impaired autonomic heart rate modulation in community-dwelling old adults. Arch Gerontol Geriatr. 2018 May;76:120–4.

14. Kocyigit SE, Soysal P, Bulut EA, Aydin AE, Dokuzlar O, Isik AT. What is the relationship between frailty and orthostatic hypotension in older adults? J Geriatr Cardiol. 2019 Mar;16(3):272–9.

15. Kocyigit SE, Soysal P, Ates Bulut E, Isik AT. Malnutrition and Malnutrition Risk Can Be Associated with Systolic Orthostatic Hypotension in Older Adults. J Nutr Heal Aging. 2018;

16. Unutmaz GD, Soysal P, Tuven B, Isik AT. Costs of medication in older patients: Before and after comprehensive geriatric assessment. Clin Interv Aging. 2018;

17. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan;48(1):16–31.

18. Ates Bulut E, Soysal P, Aydin AE, Dokuzlar O, Kocyigit SE, Isik AT. Vitamin B12 deficiency might be related to sarcopenia in older adults. Exp Gerontol. 2017; 95: 136-140.

19. Frith J, Parry SW. New Horizons in orthostatic hypotension. Age Ageing. 2017 Mar;46(2):168–74.

20. Christensen MG, Piper KS, Dreier R, Suetta C, Andersen HE. Prevalence of sarcopenia in a Danish geriatric out-patient population. Dan Med J. 2018 Jun;65(6).

21. Rowel LB. Human Cardiovascular Control. 1th ed. Oxford University Press. UK, England; 1993.

22. Rowel LB. Human Cardiovascular Control. 1th ed. UK: Oxford University Press; 1993.

23. Suzuki Y, Murakami T, Kawakubo K, Haruna Y, Takenaka K, Goto S, et al. Regional changes in muscle mass and strength following 20 days of bed rest, and the effects on orthostatic tolerance capacity in young subjects. J gravitational Physiol a J Int Soc Gravitational Physiol. 1994 May;1(1):P57-8.

24. Kobayashi K, Yamada S. Development of a simple index, calf mass index, for screening for orthostatic hypotension in community-dwelling elderly. Arch Gerontol Geriatr. 2012;54(2):293–7.

25. Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: As easy as A, B, C. Cleve Clin J Med. 2010 May;77(5):298–306.

26. Elaine Shanahan, Tina Sheehy, Aine Costelloe, Catherine Peters, Declan Lyons MO. RELATIONSHIP BETWEEN SKELETAL MUSCLE MASS AND ORTHOSTATIC HYPOTENSION. Age Ageing. 2016;45(2):ii13–ii56.

27. Soysal P, Aydin AE, Koc Okudur S, Isik AT. When should orthostatic blood pressure changes be evaluated in elderly: 1st, 3rd or 5th minute? Arch Gerontol Geriatr. 2016;65.

28. Juraschek SP, Daya N, Rawlings AM, Appel LJ, Miller ER 3rd, Windham BG, et al. Association of History of Dizziness and Long-term Adverse Outcomes With Early vs Later Orthostatic Hypotension Assessment Times in Middle-aged Adults. JAMA Intern Med. 2017 Sep;177(9):1316–23.

**LEGENDS**

**Figure 1. Prisma Flow Chart**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Robust(n:207) | Probablesarcopenia(n:216 |  Sarcopenia(n:31) | Severe Sarcopenia(n:57) | *p value* |
| ***DEMOGRAPHIC FEATURES*** |
| Age (***mean+/-SD***) | 72.57±6.90 | 76.31±6.75 | 77.10±7.67 | 81.30±6.33 | ***<0.001*** |
| Gender (female %) | 66.2 | 63.0 | 96.8 | 94.7 | ***<0.001*** |
| Education year (***median [IQR])*****Table 1. Comparisons of Patient characteristics, and OH1, OH3 and OH5 according to sarcopenia stages**  | 5 [0] | 5 [1] | 5 [3] | 5 [0] | ***<0.001*** |
| BMI(kg/m2) ***(mean+/-SD)*** | 28.82±5.00 | 29.51±4.92 | 25.25±3.38 | 24.93±4.51 | ***<0.001*** |
| ***COMORBIDITIES (%)*** |
| Falls | 33.3 | 43.5 | 38.7 | 68.4 | ***0.003*** |
| Dementia | 11.7 | 27.6 | 33.3 | 33.9 | ***<0.001*** |
| Cerebrovascular Disease | 8.2 | 5.1 | 9.7 | 8.8 | *0.434* |
| Peripheral Vascular Disease | 7.2 | 8.8 | 9.7 | 5.3 | *0.400* |
| Depression | 44.4 | 45.8 | 51.6 | 57.9 | *0.450* |
| Hypertension | 59.9 | 70.4 | 58.1 | 73.7 | *0.092* |
| Diabetes Mellitus | 30.4 | 30.1 | 29.0 | 24.6 | *0.845* |
| Hyperlipidaemia | 18.4 | 18.1 | 19.4 | 22.8 | *0.647* |
| Coronary Artery Disease | 19.3 | 19.0 | 25.8 | 21.1 | *0.859* |
| Congestive Heart Failure | 5.8 | 6.9 | 3.2 | 10.5 | *0.701* |
| COPD | 11.6 | 13.4 | 6.5 | 7.0 | *0.167* |
| Hypothyroidism | 18.8 | 23.6 | 25.8 | 21.1 | *0.705* |
| Number of Drugs *( median [IQR])* | 4 [4] | 5 [4] | 5 [5] | 7 [4] | ***0.016*** |
| ***CLASS OF DRUGS (%)*** |
| ARB | 35.5 | 34.2 | 22.6 | 32.7 | *0.782* |
| ACE | 11.8 | 14.9 | 9.7 | 12.7 | *0.370* |
| Beta-blockers | 28.1 | 33.7 | 29.0 | 36.4 | *0.224* |
| Calcium Channel Blockers | 20.7 | 29.7 | 25.8 | 34.5 | *0.085* |
| Diuretics | 34.0 | 38.1 | 25.8 | 41.8 | *0.387* |
| Alfa-blockers | 10.8 | 8.4 | 3.2 | 7.3 | *0.409* |
| Insulin | 3.9 | 7.9 | 9.7 | 9.1 | *0.090* |
| Antidepressants | 34.5 | 41.1 | 22.6 | 49.1 | *0.170* |
| Antipsychotics | 3.9 | 6.9 | 0 | 14.5 | *0.184* |
| Anti-parkinson drugs | 6.4 | 9.4 | 3.2 | 7.3 | *0.263* |
| ***LABORATORY FINDINGS***  |
| Haemoglobin (g/dL) ***(mean+/-SD)*** | 13.02±1.32 | 12.44±1.38 | 12.33±1.70 | 12.35±1.18 | ***0.001*** |
| Glucose (mg/dL)  ***(median [IQR])*** | 98.50 [37] | 99.50 [43] | 98 [46] | 103 [48] | *0.725* |
| Albumin (g/L) ***(mean+/-SD)*** | 4.08±0.32 | 3.96±0.35 | 3.99±0.41 | 3.86±0.36 | ***0.001*** |
| TSH (mg/dL)  ***(median [IQR])*** | 1.24 [1.15] | 1.34 [1.16] | 1.51 [1.29] | 1.24 [1.15] | *0.261* |
| Vitamin B12(pg/mL)  ***(median [IQR])*** | 289 [209] | 330 [259] | 278 [310] | 322 [547] | *0.208* |
| 25(OH)D (ng/mL) ***(mean+/-SD)*** | 24.26±12.29 | 22.85±10.00 | 26.96±17.79 | 29.99±20.94 | ***0.039*** |
| ***COMPREHENSIVE GERIATRIC ASSESSMENT ( median [IQR])*** |
| MMSE | 27 [5] | 23 [6] | 23 [7] | 18 [6] | ***<0.001*** |
| YGDS | 2 [5] | 3 [5] | 3 [5] | 4 [9] | ***0.017*** |
| Basic ADLs | 95 [10] | 90 [15] | 95 [25] | 75 [30] | ***<0.001*** |
| Instrumental ADLs | 21 [6] | 17 [5] | 21 [7] | 10 [13] | ***<0.001*** |
| Tinetti-Gait | 12 [1] | 11 [3] | 12 [2] | 9 [4] | ***<0.001*** |
| Tinetti-Balance | 16 [2] | 14 [4] | 15 [2] | 10 [6] | ***<0.001*** |
| Tinetti-Total | 27 [3] | 25 [7] | 26 [4] | 19 [8] | ***<0.001*** |
| Up&Go Test  | 11 [4] | 14 [8] | 12 [6] | 24 [15] | ***<0.001*** |
| MNA | 13 [2] | 13 [2] | 13 [5] | 11 [2] | ***<0.001*** |
| ***ORTHOSTATIC HYPOTENSION (OH) (%)*** |
| Systolic OH1 | 14.0 | 19.9 | 9.7 | 31.6 | ***0.037*** |
| Diastolic OH1 | 6.8 | 9.7 | 12.9 | 14.0 | *0.303* |
| OH1 | 15.9 | 25.0 | 22.6 | 38.6 | ***0.011*** |
| Systolic OH3 | 15.5 | 17.6 | 16.1 | 25.0 | *0.297* |
| Diastolic OH3 | 7.7 | 7.9 | 12.9 | 12.5 | *0.433* |
| OH3 | 19.8 | 20.4 | 29.0 | 28.6 | *0.199* |
| Systolic OH5 | 14.5 | 17.6 | 19.4 | 32.1 | *0.071* |
| Diastolic OH5 | 8.2 | 12.0 | 12.9 | 12.5 | *0.662* |
| OH5 | 18.8 | 21.8 | 25.8 | 41.1 | ***0.011*** |

25(OH)D: 25-hydroxyvitamin D; ACEI: angiotensin-converting enzyme inhibitor; ADLs: activities of daily living; ARB: angiotensin receptor blockers; BMI: body mass index; COPD: chronic obstructive pulmonary disease; IQR: Inter Quartile Range; MMSE: Mini-Mental State Examination; MNA: Mini-Nutritional Assessment;; OH: orthostatic Hypotension; OH1: OH at 1st  min; OH3: OH at 3rd min; OH5: OH at 5th min; TSH: thyroid-stimulating hormone; YGDS: Yesavage Geriatric Depression Scale

|  |  |
| --- | --- |
|  | BETWEEN ROBUST AND PROBABLE SARCOPENIA GROUP\* |
|  | Exp (B)\*\* | CI 95% | p |
| OH1 | 1.34 | 0.78-2.31 | 0.278 |
|  | BETWEEN SEVERE SARCOPENIA AND ROBUST GROUP\* |
|  | Exp (B)\*\* | CI 95% | p |
| sysOH1 | **3.26** | **0.98-10.84** | **0.05** |
| OH1 | **4.31** | **1.31-14.15** | **0.016** |
| sysOH5 | **4.09** | **1.01-16.55** | **0.048** |
| OH5 | 2.18 | 0.65-7.24 | 0.203 |
|  | BETWEEN SARCOPENIA AND SEVERE SARCOPENIA GROUP\* |
|  | Exp (B)\*\* | CI 95% | p |
| sysOH1 | **2.64** | **1.87-8.73** | **0.012** |
|  | BETWEEN SEVERE SARCOPENIA AND PROBABLE SARCOPENIA GROUP\* |
|  | Exp (B)\*\* | CI 95% | **p** |
| OH1 | **3.50** | **1.34-9.11** | **0.010** |
| sysOH5 | **3.24** | **1.13-9.23** | **0.009** |
| OH5 | **3.50** | **1.31-9.35** | **0.004** |

Exp (B): Expected B; CI: Confidence Interval; OH: Orthostatic Hypotension; OH1: OH at 1st  min, OH3: OH at 3rd min, OH5: OH at 5th min; Sys: Systolic

\*Independently age, body mass index, gender, education year, falls history, presence of dementia, Mini Mental State Examination, Yesavage Geriatric Depression Scale, Tinetti-gait and balance test, Tinetti total score, Up and go test score, Activities of Daily Living (Barthel and Lawton), and Mini Nutritional Assessment score.

\*\*All odds ratios showed a positive correlation.

Table 2. The relation between OH and different stages of sarcopenia by Binary Logistic Regression Analysis

Table 3- The relationship between muscle power, muscle mass, walking speed and OH.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Low Muscle Mass(%) | p value | Low Muscle Power(%) | p value | Low Walking Speed(%) | p value |
| Sys OH1(+/-) | 30.1/22.2 | 0.107 | 68.8/57.4 | 0.546\* | 55.9/35.4 | **0.005\*** |
| Dia OH1(+/-) | 34.0/22.6 | 0.079 | 70.2/58.4 | 0.116 | 51.1/37.9 | 0.079 |
| OH1(+/-) | 31.9/21.3 | 0.253\* | 71.6/55.9 | 0.168\* | 53.4/34.9 | **0.026\*** |
| SysOH3(+/-) | 36.0/20.9 | 0.053\* | 64.0/58.4 | 0.327 | 53.9/35.9 | **0.049\*** |
| Dia OH3(+/-) | 34.1/22.5 | 0.084 | 63.6/59.0 | 0.551 | 45.5/38.4 | 0.360 |
| OH3(+/-) | 35.5/20.3 | **0.030\*** | 62.7/58.5 | 0.424 | 50.0/36.0 | 0.060 |
| SysOH5(+/-) | 37.0/20.6 | **0.024\*** | 67.4/57.7 | 0.085 | 52.2/36.1 | 0.065\* |
| Dia OH5(+/-) | 31.5/22.6 | 0.145 | 68.5/58.3 | 0.150 | 57.4/36.8 | **0.015\*** |
| OH5(+/-) | 37.6/19.3 | **0.019\*** | 66.7/57.3 | 0.069 | 54.7/34.4 | **0.012\*** |

Dia: Diastolic; Exp (B): Expected B; CI: Confidence Interval; OH: Orthostatic Hypotension; OH1: OH at 1st min, OH3: OH at 3rd min, OH5: OH at 5th min; Sys: Systolic

\*p value, adjusted for age, presence of dementia, fall history, Timed up and go score and Activities of Daily Living (Barthel and Lawton)

